ARKK
CDNA
ARK keeps the scissors handy
Cathie Wood’s ARK ETF filed its daily trade blotter for Thursday, and the biggest headline was a pretty clean exit move: ARK sold 210,601 shares of CareDx, worth about $3.7 million. That’s not pocket change, even for a fund that likes to move fast and break things.
Why you should care
Whenever ARK trims a name, the market tends to treat it like a tiny Rorschach test. Is this just routine portfolio housekeeping, or does it hint at a cooler view on the stock? Either way, it matters because ARK trades can nudge sentiment — especially in names investors already watch for big swings.
The bigger picture
This isn’t a flashy merger or a grand thesis shift. It’s more like a portfolio manager saying, “Thanks for the ride, but we’re making room for something else.” In ARK-world, that can mean anything from risk control to a better opportunity popping up somewhere else in the biotech sandbox.
Big picture: the stock sale itself may not rewrite CareDx’s story, but it does remind you that ARK’s conviction can change fast — and when it does, the trading tape usually gets the memo.